ClinicalTrials.gg
Status unknownNCT01088282Updated Mar 17, 2010

Visual and Economic Profits of ReSTOR® Multifocal Intraocular Lenses (IOL) on Public Health Patients in Spain

An interventional study of Cataract surgery in Presbyopia, sponsored by University of Barcelona. Status unknown at 2 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-03-17.

Sponsored by University of Barcelona · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2010), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Presbyopia with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Presbyopia · Spain.

Planned enrollment
3rd of 12
120 · median 60
Started
2010
the only one that year
No phase
10 of 15
3 open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
University of Barcelona

Among the 15 studies in Presbyopia with a site in Spain, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2010, is one of 10 with no phase, and was the 2nd registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

4 of the 15 studies in Presbyopia with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Presbyopia with a site in Spain, or all of them as a file.
02

Study summary

Surgical correction of presbyopia is possible via the implantation of multifocal intraocular lenses after removal of the crystalline lens. The cost of these implants is approximately 6 times higher than the conventional monofocal implants routinely used in all crystalline surgery for correction of the resulting ametropia. Spectacles for correcting presbyopia, which are necessary after the insertion of monofocal implants, may also have a significant cost.

The proposed trial will involve two randomized groups of patients in need of crystalline/cataract surgery, with monofocal or multifocal lens implants (the same type of lens in both eyes) leaving them emmetropic for distant vision.

The objective is to corroborate with blind-evaluation the effectiveness of multifocal lens implants in obviating the need for glasses to correct presbyopia, to evaluate the benefits of this type of implant, both in global economic terms (adding the cost of the implants to that of corrective glasses where necessary) and in terms of the improved quality of life of the patients, and to confirm the absence of adverse effects.

Findings will be subjected to a statistical quantification.

03

Conditions studied

  • Presbyopia

Browse trials for

Keywords

  • Diffractive multifocal IOL
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged 50 and over, with fully-established presbyopia, requiring phacoemulsification + IOL as the surgical technique for the removal of their cataracts.
  • Their capsular bags should be stable, with keratometric astigmatism equal to or lower than 1 diopter.
  • Biometric calculations should indicate an IOL for emmetropy within the common dioptric range for both lenses, i.e. between +6 y +34.

Exclusion criteria

Exclusion Criteria:

  • Previous corneal refractive surgery
  • Maculopathy, amblyopia or other eye conditions that limit visual power
  • Occupations requiring special driving licenses
  • Keratometric astigmatism higher than 1 diopter
  • Any intraoperative posterior capsular rupture or extracapsular reconversion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Implantation of difractive multifocal IOL

    Procedure: Cataract surgery

  • Sham comparator
    Implantation of monofocal IOL

    Procedure: Cataract surgery

Interventions

  • ProcedureCataract surgery

    Implantation of multifocal or monofocal IOL

    Also known as: SN6AD1 (Alcon labs, Fotworth, Texas) in active comparator, SN60WF (Alcon labs, Fotworth, Texas) in sham comparator

06

What researchers measure

Primary outcomes

  1. Visual function quality (VF-14)

    Time frame: At 1 and 3 months post-intervention

Secondary outcomes

  1. Visual acuity with and without correction

    Time frame: at 1 and 3 months post-intervention

  2. Determine Expense in glasses

    Time frame: at 3 months post-intervention

07

Study locations

2 sites
  • Hospital Clinic. Casa Maternitat
    Barcelona, 08028, Spain
    • Josep Torras, MD · Contactjtorras@gmail.com · +34 932275667
    • Josep Torras, MD · Principal investigator
  • Hospital Clinic. Casa maternitat
    Barcelona, 08028, Spain
    • Josep Torras, MD · Contactjtorras@clinic.ub.es · +34932275667
    • Josep Torras, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Dec 2010 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2010
First posted
Mar 17, 2010
Start
Mar 2010
Primary completionEst.
Dec 2010
CompletionEst.
Mar 2011
Last update
Mar 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01088282
First posted
Mar 17, 2010
Start date
Mar 2010
Primary completion
Dec 2010 (estimated)
Completion
Mar 2011 (estimated)
Last update
Mar 17, 2010

Study contacts

Josep Torras, MD
Contact
jtorras@clinic.ub.es
+34 932275667
Josep Torras, MD
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion